Sugi Predict

Sugi Predict / Compounds / SCHEMBL732122

SCHEMBL732122

SCHEMBL732122

O=Cc1cccc2scnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ CYP2A6 P11509 2/20 0.40
▸ TDP1 Q9NUW8 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ TRIM24 O15164 2/20 0.37
▸ TRIM33 Q9UPN9 2/20 0.37
▸ ERN1 O75460 2/20 0.35
▸ CCR1 P32246 1/20 0.34
▸ CCR5 P51681 1/20 0.34
▸ CCR8 P51685 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ TSHR P16473 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7221909 0.81 ALDH1A1 (0.41) ALDH1A1HSD17B10DYRK1ADYRK2DYRK1B
SCHEMBL17361321 0.81 ALDH1A1 (0.41) ALDH1A1HSD17B10DYRK1ADYRK2DYRK1B
SCHEMBL21712219 0.74 ALDH1A1 (0.34) ALDH1A1HSD17B10CYP2A6TDP1MEN1
SCHEMBL9111226 0.74 ALDH1A1 (0.35) ALDH1A1HSD17B10NAMPT
SCHEMBL2088376 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10TDP1NAMPTKDM4E
SCHEMBL28590373 0.73 ERN1 (0.36) ERN1NAMPT
SCHEMBL197613 0.69 ALDH1A1 (0.45) ALDH1A1HSD17B10NAMPTL3MBTL1PRMT5
SCHEMBL288904 0.69 ALDH1A1 (0.46) ALDH1A1HSD17B10CYP2A6LMNASMN1; SMN2
SCHEMBL926998 0.69 LMNA (0.46) ALDH1A1HSD17B10CYP2A6TDP1MEN1
SCHEMBL288903 0.69 ALDH1A1 (0.45) ALDH1A1HSD17B10NAMPTPRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 — — US claimed
CN-105612162-B Thiazolopyrimidinones as modulators of NMDA receptor activity 豪夫迈·罗氏有限公司 2018-08-21 — — CN claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 — — US claimed
WO-2023201012-A1 IKZF2 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-10-19 — — WO disclosed
EP-3183250-B1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL CLAP CO LTD (KR) 2023-10-04 — — EP disclosed
WO-2023180189-A1 MPRO TARGETING ANTIVIRAL COMPOUNDS EXSCIENTIA AI LIMITED (GB) 2023-09-28 — — WO disclosed
EP-3183757-B1 ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM CLAP CO LTD (KR) 2022-05-04 — — EP disclosed
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 — — US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 — — US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 — — US disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 — — EP disclosed
WO-2016027218-A1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL BASF SE (DE) 2016-02-25 — — WO disclosed
US-20140042369-A1 Organic Semiconductor Formulations USINVEST LLC 2014-02-13 — — US disclosed
US-8138337-B2 Reverse-turn mimetics and method relating thereto CHOONGWAE PHARMA CORPORATION (KR) 2012-03-20 — — US disclosed
US-8049008-B2 Reverse-turn mimetics and method relating thereto CHOONGWAE PHARMA CORPORATION (KR) 2011-11-01 — — US disclosed
CN-102015715-A Fused pyrimidones as TRPV3 modulators GLENMARK PHARMACEUTICALS SA 2011-04-13 — — CN disclosed
US-20100240662-A1 REVERSE-TURN MIMETICS AND METHOD RELATING THERETO CHOONGWAE PHARMA CORPORATION (KR) 2010-09-23 — — US disclosed
US-20100222303-A1 REVERSE-TURN MIMETICS AND METHOD RELATING THERETO CHOONGWAE PHARMA CORPORATION (KR) 2010-09-02 — — US disclosed
US-7671054-B1 Reverse-turn mimetics and method relating thereto CHOONGWAE PHARMA CORPORATION (KR) 2010-03-02 — — US disclosed
CN-1122038-C Heterocycle-fused thiazole derivatives YUNJIAN PHARMACEUTICAL CO LTD (KR) 2003-09-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399235-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 ALDH1A1 1103/4885HSD17B10 651/4885CYP2A6 2396/4885
US-20100222303-A1 REVERSE-TURN MIMETICS AND METHOD RELATING THERETO WNT1, WNT3, APC ALDH1A1 3409/4885HSD17B10 3783/4885CYP2A6 2021/4885
US-20100240662-A1 REVERSE-TURN MIMETICS AND METHOD RELATING THERETO WNT1, WNT3, APC ALDH1A1 3409/4885HSD17B10 3783/4885CYP2A6 2021/4885
US-10889555-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 ALDH1A1 1103/4885HSD17B10 651/4885CYP2A6 2396/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR ALDH1A1 4757/4885HSD17B10 4363/4885CYP2A6 2194/4885
US-20200405697-A1 Antitumor Agent HNRNPR, RRM2, RRM2B ALDH1A1 1397/4885HSD17B10 1842/4885CYP2A6 3134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.